Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + SOX vs SOX as Adjuvant Therapy for Gastric/GEJ Adenocarcinoma
NCT07492615Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Started Jan 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07492615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492615.